Intellectual Property India Publishes Patent Application for Combination Of Iap Inhibitors And Cellular Kinase Inhibitors, Such As Ponatinib, For Use In The Treatment Of Cancer Or Pulmonary Diseases, Such As Copd, Cystic Fibrosis, Pulmonary Fibrosis And Covid-19

MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202617062920 A) filed by University Of Houston System; and Tract Pharmaceuticals, Inc. on May 18, 2026, for Combination Of Iap Inhibitors And Cellular Kinase Inhibitors, Such As Ponatinib, For Use In The Treatment Of Cancer Or Pulmonary Diseases, Such As Copd, Cystic Fibrosis, Pulmonary Fibrosis And Covid-19.

Inventors include Xian, Wa; Mckeon, Frank; Vincent, Matthew; and Russell, Richard E..

The application for the patent was published on June 12, 2026, under issue no. 24/2026.

Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Disclaimer: Curated by HT Syndication.